Neuland Laboratories share price
NSE: NEULANDLABBSE: 524558Pharmaceuticals & BiotechnologySmall Cap
Neuland Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1994 on BSE, Oct 2008 on NSE
Last close ₹19,970.00up ₹655.00 (3.39%)BSE ₹20,015.65
Share price at the NSE close on 28 Oct 2026. Previous close ₹19,315.00.
28 Oct: open ₹19,200.00, high ₹20,095.00, low ₹19,200.00
52-week range of traded prices to 28 Oct 2026
₹11,500.00Low, 23 Mar 2026₹24,225.00High, 9 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹25,621 Cr356th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 51.47
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 13.67
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.17%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 29.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 32.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 31,72747.6% delivered
About Neuland Laboratories
Neuland Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients (APIs, the substance in a medicine that produces its effect) for pharmaceutical and biotechnology companies.12 Its Custom Manufacturing Solutions (CMS) business develops and makes APIs and intermediates for new drugs under exclusive contracts with innovators; its Generic Drug Substances (GDS) business makes non-exclusive generic APIs for regulated markets.134 It chooses not to compete with its customers in generic finished medicines.5
GDS sells Prime APIs, large-volume mature molecules such as Mirtazapine, Ezetimibe and Escitalopram, and Specialty APIs, complex low-volume molecules such as Apixaban, Paliperidone Palmitate Sterile, Donepezil and Dorzolamide.46 Davuluri Rama Mohan Rao founded the company in 1984 and is its Executive Chairman.7 Its shares were listed in 1994, US operations began in 2004, and in 2018 it bought the advanced intermediates and API plant that is now Unit III.89
It runs 3 manufacturing units around Hyderabad and an R&D centre there, with business development offices in Princeton (US), Lugano (Switzerland) and Tokyo.101112 Its wholly owned subsidiaries, Neuland Laboratories K.K. in Japan and Neuland Laboratories Inc. in the US, provide marketing and business support.13 Davuluri Saharsh Rao is Chief Executive Officer and Managing Director; Davuluri Sucheth Rao, chief executive from 2009 until March 2026, is Executive Vice-Chairman.14 Promoters held 33% of the shares at the end of June 2026.15
Neuland Laboratories key points
Results
- On a standalone basis (the company alone, without its subsidiaries), total income for the quarter to Jun 2026 was ₹650.1 crore against ₹300.6 crore a year earlier, and profit after tax ₹147.4 crore against ₹13.7 crore.1617
- Standalone EBITDA (earnings before interest, tax, depreciation and amortisation) for the quarter to Jun 2026 was ₹231.1 crore, a margin of 35.5%.1816
- In the year to Mar 2026, standalone total income crossed ₹2,000 crore, at ₹2,053.1 crore against ₹1,497.3 crore a year earlier. The company said favourable foreign exchange movements also contributed to the year's results.1920
- Standalone EBITDA for the year to Mar 2026 was ₹603.4 crore against ₹342.8 crore a year earlier, a margin of 29.4% against 22.9%, and profit after tax was ₹363.1 crore against ₹259.4 crore.2120
Where revenue comes from
Plants and capacity
- API manufacturing capacity by plant, in kilolitres (kL) of reactor volume2425Total API manufacturing capacity is 1,226 kL.
Item quarter to Jun 2026 Unit III, Gaddapotharam 581 kL Unit II, Pashamylaram 389 kL Unit I, Bonthapally 256 kL - In the year to Mar 2026, Unit III commissioned a new 52 kL block and Unit I added a 19 kL block for large-volume generic products.2627
Custom manufacturing (CMS)
- Active CMS projects by stage, end of June 202628Phases 1 to 3 are clinical trials in people.
Item quarter to Jun 2026 Pre-clinical 17 Phase 1 23 Phase 2 20 Phase 3 13 Pre-registration or registration 7 Commercial 19 Total 99 - On its earnings call of 5 Aug 2026, the company said its commercial CMS business is driven by a handful of molecules, maybe about 3, and that orders for them may not come every quarter.29
- In the year to Mar 2026, the CMS business worked with 39 customers, on more projects than a year earlier.30
- On its earnings call of 5 Aug 2026, the company said it expects 1 more CMS molecule to become commercial this year, and probably 1, maybe 2, next year.31
Generic APIs (GDS)
- In the year to Mar 2026, the Generic Drug Substances business saw a dip, which the company attributes to a few key products; some customers' regulatory problems cut expected volumes of certain profitable products.3233
- On its earnings call of 5 Aug 2026, the company described a strategic collaboration with Gland Pharma in sterile APIs for niche generics, an asset-light arrangement for Neuland.3435
- In the year to Mar 2026, Neuland filed 2 new Drug Master Files (DMFs, dossiers regulators use to review an API maker), for Vonoprazan and Edoxaban.36
- Across the company, Neuland had filed more than 1,010 DMFs worldwide and had 75 active US DMFs as of June 2026.37
Expansion and capital spending
- On its earnings call of 5 Aug 2026, the company said it had approved ₹1,460 crore of capital spending over the last 13 quarters and spent ₹870 crore of it, with the balance committed to projects under implementation.38
- The company stated in its annual report for the year to Mar 2026 that it plans ₹254 crore of spending to raise peptide (short chains of amino acids used as medicines) reactor capacity from 0.5 kL to 6.37 kL.39
- The company stated in its annual report for the year to Mar 2026 that it is moving R&D to a new campus of around 135,000 to 140,000 sq. ft. in Hyderabad's Genome Valley, backed by around ₹190 crore.4041
What the company expects
- On its earnings call of 5 Aug 2026, the company said it has always aspired to grow about 20% and expects to grow that way in the years to Mar 2027 and Mar 2028, but would not commit to a growth rate.42
- On its earnings call of 5 Aug 2026, the company said it plans for an EBITDA margin of 25% plus over the long term, noting favourable exchange rates.43
Recent events
- The US FDA inspected Unit III from 10 to 14 Aug 2026 and issued a Form 483 (a list of inspection observations) with 1 observation, on water and environmental monitoring. On 14 Oct 2026, the company said the FDA had closed the inspection.4445
- On 25 Aug 2026, Crisil Ratings reaffirmed the company's long-term credit rating (an agency's view of its ability to repay debt) at CRISIL A+, revised its outlook to Positive, and reaffirmed its short-term rating at CRISIL A1.46
- On 13 Jul 2026, India Ratings and Research affirmed the company's bank loan rating at IND A+/Positive/IND A1.47
Last updated
All 47 sources, each with its page
- 1. Annual report, 9 Jul 2026, page 5
- 2. Annual report, 9 Jul 2026, page 81
- 3. Annual report, 9 Jul 2026, page 10
- 4. Annual report, 9 Jul 2026, page 8
- 5. Annual report, 9 Jul 2026, page 67
- 6. Annual report, 9 Jul 2026, page 82
- 7. Annual report, 9 Jul 2026, page 18
- 8. Annual report, 9 Jul 2026, page 12
- 9. Investor presentation, 5 Aug 2026, page 16
- 10. Annual report, 9 Jul 2026, page 6
- 11. Annual report, 9 Jul 2026, page 42
- 12. Investor presentation, 5 Aug 2026, page 17
- 13. Annual report, 9 Jul 2026, page 40
- 14. Annual report, 9 Jul 2026, page 18
- 15. Investor presentation, 5 Aug 2026, page 28
- 16. Investor presentation, 5 Aug 2026, page 30
- 17. Earnings call, 5 Aug 2026, page 3
- 18. Earnings call, 5 Aug 2026, page 3
- 19. Annual report, 9 Jul 2026, page 14
- 20. Annual report, 9 Jul 2026, page 4
- 21. Annual report, 9 Jul 2026, page 83
- 22. Investor presentation, 5 Aug 2026, page 17
- 23. Investor presentation, 5 Aug 2026, page 14
- 24. Investor presentation, 5 Aug 2026, page 18
- 25. Investor presentation, 5 Aug 2026, page 14
- 26. Annual report, 9 Jul 2026, page 42
- 27. Annual report, 9 Jul 2026, page 42
- 28. Investor presentation, 5 Aug 2026, page 11
- 29. Earnings call, 5 Aug 2026, page 8
- 30. Annual report, 9 Jul 2026, page 47
- 31. Earnings call, 5 Aug 2026, page 9
- 32. Annual report, 9 Jul 2026, page 86
- 33. Annual report, 9 Jul 2026, page 14
- 34. Earnings call, 5 Aug 2026, page 6
- 35. Earnings call, 5 Aug 2026, page 14
- 36. Annual report, 9 Jul 2026, page 82
- 37. Investor presentation, 5 Aug 2026, page 14
- 38. Earnings call, 5 Aug 2026, page 4
- 39. Annual report, 9 Jul 2026, page 20
- 40. Annual report, 9 Jul 2026, page 46
- 41. Annual report, 9 Jul 2026, page 82
- 42. Earnings call, 5 Aug 2026, page 7
- 43. Earnings call, 5 Aug 2026, page 14
- 44. Exchange filing, 14 Oct 2026, page 1
- 45. Exchange filing, 14 Aug 2026, page 1
- 46. Exchange filing, 25 Aug 2026, page 1
- 47. Exchange filing, 13 Jul 2026, page 1
Results
Consolidated; ₹ crore.Neuland Laboratories quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +78.3%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +182.6%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹642 Crdown 17.35%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹148 Crdown 30.56%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 23.0%
Revenue by quarter
Peak revenue ₹776 Cr, quarter to Mar 2026; lowest ₹293 Cr, quarter to Jun 2025
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 311 | 398 | 328 | 293 | 514 | 440 | 776 | 642 |
| Net profit | 33 | 102 | 28 | 14 | 97 | 41 | 213 | 148 |
| Net margin | 10.6% | 25.5% | 8.5% | 4.7% | 18.8% | 9.2% | 27.4% | 23.0% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹2,023 Crup 36.98%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹364 Crup 39.94%
- Net margin
- 18.0%
Revenue by year
Peak revenue ₹2,023 Cr, year to Mar 2026; lowest ₹529 Cr, year to Mar 2018
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 573 | 529 | 667 | 763 | 937 | 951 | 1,191 | 1,559 | 1,477 | 2,023 |
| Net profit | 33 | 12 | 16 | 16 | 81 | 64 | 164 | 300 | 260 | 364 |
| Net margin | 5.7% | 2.3% | 2.5% | 2.1% | 8.6% | 6.7% | 13.7% | 19.3% | 17.6% | 18.0% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Manufacturing of Active Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.Neuland Laboratories PE ratio and valuation
Price to earnings
At or below today's level on 73% of 2,448 trading days over the last 10 years.
LowestHighest
Its median38.10Industry median27.98
Price to book
At or below today's level on 95% of 1,977 trading days since Nov 2018.
LowestHighest
Its median3.04Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 55% of 2,457 trading days over the last 10 years.
LowestHighest
Its median0.16%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −0.1% | +39.9% | −28.8% | 0.3% |
| 3 years | +88.4% | +30.6% | +44.1% | 0.2% |
| 5 years | +42.2% | +35.2% | +5.0% | 0.3% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 year includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2025.
Mutual fund holdings
127 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 52 of the 70 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 127 funds holding Neuland Laboratories
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 4
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 29
- CutCut. Funds that held fewer shares than at the end of the month before.
- 41
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 51
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 1
| Fund | |||
|---|---|---|---|
 HDFC Flexi Cap FundHDFC Mutual Fund | 2,78,894 | 0.55% | ₹595.4 Cr |
 HSBC Small Cap FundHSBC Mutual Fund | 1,61,529 | 1.86% | ₹344.9 Cr |
 ICICI Prudential Flexi Cap FundICICI Prudential Mutual Fund | 1,47,477 | 1.25% | ₹314.9 Cr |
 Mahindra Manulife Multi Cap FundMahindra Manulife Mutual Fund | 95,343 | 2.73% | ₹203.6 Cr |
| Mahindra Manulife Small Cap FundMahindra Manulife Mutual Fund | 61,078 | 2.43% | ₹130.4 Cr |
 Bajaj Finserv Flexi Cap FundBajaj Finserv Mutual Fund | 55,985 | 1.40% | ₹119.5 Cr |
| HDFC Pharma and Healthcare FundHDFC Mutual Fund | 53,164 | 3.24% | ₹113.5 Cr |
 Bandhan Small Cap FundBandhan Mutual Fund | 53,114 | 0.32% | ₹113.4 Cr |
 Mirae Asset Small Cap FundMirae Asset Mutual Fund | 48,515 | 1.78% | ₹103.6 Cr |
| ICICI Prudential Balanced Advantage FundICICI Prudential Mutual Fund | 45,345 | 0.13% | ₹96.8 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Neuland Laboratories insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 1 pledge created · 6 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Neuland Laboratories competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Neuland Laboratories in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 WockhardtWOCKPHARMA | 31,091 | 76.02 | 6.29 | +18.4% | – | 8.8% | 7.4% | 0.00% |
 Piramal PharmaPPLPHARMA | 30,994 | – | 3.81 | +9.4% | – | −2.6% | 2.3% | 0.00% |
 Acutaas ChemicalsACUTAAS | 30,374 | 69.17 | 16.35 | +45.2% | +96.1% | 26.9% | 30.2% | 0.07% |
 Rubicon ResearchRUBICON | 25,889 | 89.83 | 20.09 | – | – | 22.4% | 25.8% | 0.10% |
 Granules IndiaGRANULES | 22,926 | 34.61 | – | +24.8% | +38.1% | 15.1% | 15.1% | 0.21% |
 Shilpa MedicareSHILPAMED | 18,228 | 61.31 | 7.03 | +27.9% | +167.6% | 12.0% | 10.9% | 0.06% |
 Cohance LifesciencesCOHANCE | 18,214 | 171.45 | 4.66 | +41.2% | −58.5% | 3.8% | 3.0% | 0.00% |
 Onesource Specialty PharmaONESOURCE | 18,091 | – | 3.06 | +10.7% | −103.9% | 0.0% | 1.5% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Neuland Laboratories dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹34.00 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 24 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹34.00 |
| 18 Jul 2025 | Final | ₹12.00 |
| 12 Jul 2024 | Final | ₹14.00 |
| 11 Jul 2023 | Final | ₹10.00 |
| 14 Jul 2022 | Final | ₹5.00 |
| 29 Jun 2021 | Final | ₹3.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Neuland Laboratories announcements
Oct 2026
28 Oct · Analysts
Sep 2026
15 Sep · Business
Neuland Laboratories share price by year
Each calendar year to 2025.Neuland Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 15,175.00 | +10.6% | 18,113.00 | 10,487.30 |
| 2024 | 13,723.80 | +159.4% | 17,846.35 | 5,282.55 |
| 2023 | 5,291.40 | +217.4% | 5,466.95 | 1,398.75 |
| 2022 | 1,666.95 | +7.9% | 1,938.95 | 973.40 |
| 2021 | 1,545.05 | +41.1% | 2,695.25 | 1,090.30 |
| 2020 | 1,095.30 | +161.9% | 1,289.90 | 255.35 |
| 2019 | 418.15 | −8.8% | 784.65 | 388.15 |
| 2018 | 458.35 | −48.7% | 893.40 | 433.20 |
| 2017 | 892.85 | −13.5% | 1,601.40 | 858.35 |
| 2016 | 1,032.30 | +29.3% | 1,063.65 | 523.55 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 19,055.00 | 19,485.00 | 19,055.00 | 19,315.00 | 19,306.91 | 22,944 | 43.0% |
| 26 Oct 2026 | 18,500.00 | 19,210.00 | 18,485.00 | 19,055.00 | 18,988.70 | 25,458 | 46.9% |
| 23 Oct 2026 | 19,020.00 | 19,050.00 | 18,120.00 | 18,865.00 | 18,645.65 | 53,347 | 48.3% |
| 22 Oct 2026 | 18,985.00 | 19,125.00 | 18,530.00 | 18,935.00 | 18,881.74 | 40,442 | 59.5% |
| 21 Oct 2026 | 19,220.00 | 19,380.00 | 18,500.00 | 18,975.00 | 18,861.90 | 60,544 | 57.0% |
| 19 Oct 2026 | 19,690.00 | 19,940.00 | 19,135.00 | 19,220.00 | 19,471.75 | 31,501 | 51.8% |
| 16 Oct 2026 | 19,960.00 | 20,175.00 | 19,600.00 | 19,675.00 | 19,943.27 | 26,550 | 38.2% |
| 15 Oct 2026 | 20,350.00 | 20,400.00 | 19,805.00 | 19,955.00 | 19,977.18 | 45,292 | 59.9% |
| 14 Oct 2026 | 20,385.00 | 20,405.00 | 20,050.00 | 20,200.00 | 20,187.85 | 31,590 | 47.7% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Rights issue history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 13 Aug 2014 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
| 21 Mar 2012 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
Each event is noted and not adjusted for.
Company details
- NSE symbol
- NEULANDLAB
- BSE code
- 524558
- ISIN
- INE794A01010
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.neulandlabs.com
- CIN
- L85195TG1984PLC004393
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1984
- Registered office
- Sanali Info Park, A Block, Ground Floor, 8-2-120/113, Road No. 2, Banjara Hills, Hyderabad 500034, Telangana
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Smallcap 250, BSE 250 SmallCap Index, Nifty Smallcap 100, BSE SmallCap